公开(公告)号：US20240358779A1

公开(公告)日：2024-10-31

申请号：US18566043

申请日：2022-05-31

申请人： MD HEALTHCARE INC.

发明人： Yoon-Keun KIM

IPC分类号： A61K35/747 ,  A61K8/99 ,  A61P29/00 ,  A61Q19/08 ,  B82Y5/00

CPC分类号： A61K35/747 ,  A61K8/99 ,  A61P29/00 ,  A61Q19/08 ,  A61K2800/412 ,  A61K2800/413 ,  A61K2800/85 ,  B82Y5/00

摘要： Provided are a composition for preventing or treating diseases caused by immune dysfunction and metabolic dysfunction, including Lactobacillus bacteria-derived extracellular vesicles as an active ingredient, wherein, the Lactobacillus bacteria-derived vesicles may be distributed to major organs after being absorbed into the human body, and after being absorbed into cells, they may move to organelles to inhibit NF-κB signaling, which is a key signal of inflammatory responses, thereby regulating inflammatory responses; and the vesicles increase cell viability by activating AMPK signaling in metabolic stress situations where ATP production is poor, therefore it is expected that the vesicles may be effectively used in the development of pharmaceuticals or health functional foods for alleviating, preventing, or treating diseases caused by immune dysfunction or metabolic dysfunction.

公开(公告)号：US12128077B2

公开(公告)日：2024-10-29

申请号：US17417654

申请日：2019-08-08

申请人： Lactobio A/S

发明人： Charlotte Vedel ,  Ida Blomquist Jorgensen ,  Soren Kjaerulff

IPC分类号： A61K39/02 ,  A61K35/747 ,  A61P31/04 ,  C12N1/20 ,  C12R1/225

CPC分类号： A61K35/747 ,  A61P31/04 ,  C12N1/205 ,  C12R2001/225

摘要： The present invention relates to a bacterial strain having a genetic homology of at least 95% to one or more of the bacterial strains selected from the group consisting of:



Weissella viridescens LB10G, which is deposited as DSM 32906;
Lactobacillus paracasei LB113R, which is deposited as DSM 32907;
Lactobacillus plantarum LB244R, which is deposited as DSM 32996;
Lactobacillus paracasei LB116R, which is deposited as DSM 32908;
Enterococcus faecium LB276R, which is deposited as DSM 32997;
Lactobacillus plantarum LB316R, which is deposited as DSM 33091;
Leuconostoc mesenteriodes LB341R;
Leuconostoc mesenteriodes LB349R, which is deposited as DSM 33093;
Lactobacillus plantarum LB356R, which is deposited as DSM 33094;
Lactobacillus plantarum LB312R, which is deposited as DSM 33098.

公开(公告)号：US20240342229A1

公开(公告)日：2024-10-17

申请号：US18756561

申请日：2024-06-27

申请人： Grape King Bio Ltd

发明人： Chin-Chu CHEN ,  Yen-Lien CHEN ,  Shih-Wei LIN ,  You-Shan TSAI ,  Tzu-Chun LIN ,  Ci-Sian WANG ,  Yu-Hsin HOU ,  Yang-Tzu SHIH ,  Ching-Wen LIN ,  Ya-Jyun CHEN ,  Jia-Lin JIANG ,  Zi-He WU ,  Yen-Po CHEN

IPC分类号： A61K35/747 ,  A61K9/00 ,  A61K9/19 ,  A61K35/00 ,  C12N1/20 ,  C12R1/225 ,  C12R1/24 ,  C12R1/25

CPC分类号： A61K35/747 ,  A61K9/0053 ,  A61K9/19 ,  C12N1/205 ,  A61K2035/115 ,  C12R2001/225 ,  C12R2001/24 ,  C12R2001/25

摘要： The present disclosure relates to an anti-fatigue Lactobacillus composition. The anti-fatigue Lactobacillus composition, which includes at least one of Lactobacillus brevis GKEX, Lactobacillus plantarum GKK1 and Lactobacillus johnsonii GKJ2 as an active ingredient, administered to a healthy subject for a continuous period of time, can significantly improve fatigue-related biochemical indices and prolong aerobic exercise time to exhaustion, and thus can be used as an active ingredient for preparation of various compositions for anti-fatigue and/or improving athletic ability.

公开(公告)号：US20240335486A1

公开(公告)日：2024-10-10

申请号：US18576842

申请日：2022-07-08

申请人： SUMITOMO CHEMICAL COMPANY, LIMITED

发明人： Mikio AOKI ,  Kazuki MIKATA ,  Toshihiro KAI ,  Ikuo HIRONO ,  HIdehiro KONDO ,  Sana MATSUMOTO

IPC分类号： A61K35/747 ,  A01K61/59 ,  A23K10/16 ,  A23K50/80 ,  A61P31/04

CPC分类号： A61K35/747 ,  A01K61/59 ,  A23K10/16 ,  A23K50/80 ,  A61P31/04

摘要： Provided are: a composition for rearing an organism belonging to the order Decapoda, comprising bacterial cells or a cell culture product of at least one bacterium selected from NITE-BP-03199, NITE-BP-03200, and NITE-BP-03201, or an extract thereof; and a method for rearing an organism belonging to the order Decapoda using the same. Provided are: a composition for preventing or treating an infection caused by a Vibrio bacterium in a decapod, comprising bacterial cells or a cell culture product of at least one bacterium selected from NITE-BP-03199, NITE-BP-03200, and NITE-BP-03201, or an extract thereof; and a method for preventing or treating an infection in a decapod using the same.

公开(公告)号：US20240325468A1

公开(公告)日：2024-10-03

申请号：US18575198

申请日：2022-07-06

申请人： LISCURE BIOSCIENCES INC.

发明人： Hwa Sup CHIN

IPC分类号： A61K35/747 ,  A61P37/06 ,  C12N1/20 ,  C12R1/225

CPC分类号： A61K35/747 ,  A61P37/06 ,  C12N1/205 ,  C12R2001/225

摘要： The present disclosure relates to a composition containing Lactobacillus sakei or extracellular vesicles derived therefrom. The present disclosure also relates to a novel Lactobacillus sakei LBML6 strain. The Lactobacillus sakei according to the present disclosure is a strain which has inhibitory activity against TNFα and IgG in blood and in which the proportion of tolDC cells and Treg cells is increased, and can be used for various applications such as the prevention, alleviation and/or treatment of autoimmune disease in human or animals as well as intestinal regulation.

公开(公告)号：US20240307467A1

公开(公告)日：2024-09-19

申请号：US18274950

申请日：2021-10-28

申请人： Diego Alejandro CASTORENA VALENZUELA ,  Maria Fernanda DE LA ROSA FLORES ,  INSTITUTO TECNOLÓGICO Y DE ESTUDIOS SUPERIORES DE OCCIDENTE, A.C.

发明人： Diego Alejandro CASTORENA VALENZUELA ,  Maria Fernanda DE LA ROSA FLORES

IPC分类号： A61K35/747 ,  A61K47/26 ,  A61K47/36 ,  A61P1/02

CPC分类号： A61K35/747 ,  A61K47/26 ,  A61K47/36 ,  A61P1/02

摘要： A matrix formulated with probiotics, which can be used to reduce the development of caries by inhibiting Streptococcus mutans and wherein the probiotics include: 3-5 g/100 mL pectin; 6-9 g/100 mL dextrose; 25-50 mg/100 mL citric acid; 2-4 mL/100 mL natural flavouring; and 4×10 12 CFU/mL of the microorganisms Streptococcus salivarius and Lactobacillus plantarum in active state. The matrix is administered to a patient to prevent dental caries.

公开(公告)号：US12091652B2

公开(公告)日：2024-09-17

申请号：US17101871

申请日：2020-11-23

申请人： AOBIOME LLC

发明人： David R. Whitlock ,  Spiros Jamas ,  Larry Weiss ,  Ioannis Gryllos

IPC分类号： C12N1/20 ,  A61K8/99 ,  A61K9/00 ,  A61K35/74 ,  A61K35/744 ,  A61K35/745 ,  A61K35/747 ,  A61K48/00 ,  A61L15/36 ,  A61Q15/00 ,  A61Q17/04 ,  A61Q19/00 ,  C07K14/195 ,  C12N1/00 ,  C12Q1/02 ,  C12Q1/689 ,  A61Q19/02 ,  A61Q19/04 ,  C12R1/01

CPC分类号： C12N1/20 ,  A61K8/99 ,  A61K9/0014 ,  A61K35/74 ,  A61K35/744 ,  A61K35/745 ,  A61K35/747 ,  A61K48/00 ,  A61L15/36 ,  A61Q15/00 ,  A61Q17/04 ,  A61Q19/00 ,  C07K14/195 ,  C12N1/00 ,  C12N1/205 ,  C12Q1/02 ,  C12Q1/689 ,  A61Q19/02 ,  A61Q19/04 ,  C12R2001/01

摘要： This disclosure provides, inter alia, an optimized strain of Nitrosomonas eutropha (N. eutropha) designated D23, D23-100, or AOB D23-100. N. eutropha bacteria disclosed in this application have desirable properties, e.g., optimized properties, such as the ability to suppress growth of pathogenic bacteria, and an enhanced ability to produce nitric oxide and nitric oxide precursors. The N. eutropha herein may be used, for instance, to treat diseases associated with low nitrite levels, skin diseases, and diseases caused by pathogenic bacteria.

公开(公告)号：US12090182B2

公开(公告)日：2024-09-17

申请号：US17529474

申请日：2021-11-18

申请人： CHAMBIO CO., LTD.

发明人： Meei-Yn Lin ,  Hung-Pin Chiu ,  Yi-Heng Chiu

IPC分类号： A61K35/747 ,  A61K35/745 ,  A61P11/00

CPC分类号： A61K35/747 ,  A61K35/745 ,  A61P11/00

摘要： Disclosed herein is a method for preventing or alleviating particulate matter-induced lung injury. The method includes administering to a subject in need thereof a pharmaceutical composition including at least one heat-killed lactic acid bacterial strain that is selected from the group consisting of Lactobacillus plantarum CB102 which is deposited at the Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ) GmbH under an accession number DSM 33894, Lactobacillus acidophilus JCM 1132, Bifidobacterium longum CB108 which is deposited at the DSMZ GmbH under an accession number DSM 33895, Bifidobacterium animalis subsp. lactis JCM 10602, and combinations thereof.

公开(公告)号：US20240293486A1

公开(公告)日：2024-09-05

申请号：US18575412

申请日：2022-07-01

申请人： Duke University ,  Ann and Robert H. Lurie Children's Hospital of Chicago

发明人： Matthew Kelly ,  Patrick Seed

IPC分类号： A61K35/747 ,  A61K45/06 ,  A61P31/04 ,  C12Q1/689

CPC分类号： A61K35/747 ,  A61K45/06 ,  A61P31/04 ,  C12Q1/689

摘要： Disclosed herein are biotherapeutics comprising probiotics or a consortium of probiotics. Disclosed herein are biotherapeutics comprising factors secreted from probiotics or factors secreted from a consortium of probiotics. Disclosed herein are also pharmaceutical formulations comprising a disclosed biotherapeutic. Also disclosed are methods of promoting respiratory health, reducing the risk of developing and infection, treating and/or preventing a bacterial colonization and/or infection, and modulating microbial diversity and/or composition.

公开(公告)号：US20240277789A1

公开(公告)日：2024-08-22

申请号：US18633805

申请日：2024-04-12

申请人： CODEX LABS CORPORATION

发明人： Jessica MALOH ,  Barbara A. PALDUS ,  Raja SIVAMANI

IPC分类号： A61K35/747 ,  A61K9/00 ,  A61K31/353 ,  A61K31/57 ,  A61K35/00 ,  A61K35/742 ,  A61K35/745 ,  A61K36/328 ,  A61K36/82 ,  A61K45/06 ,  A61P17/10

CPC分类号： A61K35/747 ,  A61K9/0053 ,  A61K31/353 ,  A61K31/57 ,  A61K35/742 ,  A61K35/745 ,  A61K36/328 ,  A61K36/82 ,  A61K45/06 ,  A61P17/10 ,  A61K2035/115

摘要： The present disclosure relates to compositions and methods useful for dietary augmentation to provide therapeutic intervention for the treatment and management of acne-prone skin. According to one embodiment of the present disclosure, there is provided an orally administrable composition containing a therapeutically effective amount of: (a) a probiotic blend of bacterial components containing at least: (i) Lactobacillus acidophilus, (ii) Bifidobacterium lactis, an (iii) Bacillus coagulans; (b) guggul; and (c) green tea leaf.